Carbon monoxide-releasing molecule-3 protects against ischemic stroke by suppressing neuroinflammation and alleviating blood-brain barrier disruption

J Neuroinflammation. 2018 Jun 21;15(1):188. doi: 10.1186/s12974-018-1226-1.

Abstract

Background: At low levels, carbon monoxide (CO) has been shown to have beneficial effects on multiple organs and tissues through its potential anti-inflammatory, anti-apoptotic, and anti-proliferative properties. However, the effect of CO-releasing molecule (CORM)-3, a water-soluble CORM, on ischemic stroke and its mechanism of action are still unclear.

Methods: We investigated the role of CORM-3 in the mouse model of transient middle cerebral artery occlusion (tMCAO). CORM-3 or saline was administered to mice by retro-orbital injection at the time of reperfusion after 1-h tMCAO or at 1 h after sham surgery. We assessed infarct volume and brain water content at 24 and 72 h after ischemia, blood-brain barrier permeability at 6 and 72 h after ischemia, and neurologic deficits on days 1, 3, 7, and 14.

Results: Among mice that underwent tMCAO, those that received CORM-3 had significantly smaller infarct volume and greater expression of neuronal nuclear antigen (NeuN) and microtubule-associated protein 2 than did saline-treated mice. CORM-3-treated mice had significantly fewer activated microglia in the peri-infarction zone than did control mice and exhibited downregulated expression of ionized calcium-binding adapter molecule (Iba)-1, tumor necrosis factor-α, and interleukin 1β. CORM-3-treated mice had significantly lower brain water content and enhanced neurologic outcomes on days 3, 7, and 14 post-tMCAO. Lastly, CORM-3 treatment reduced Evans blue leakage; increased expression of platelet-derived growth factor receptor-β, tight junction protein ZO-1, and matrix protein laminin; and decreased protein level of matrix metalloproteinase-9.

Conclusion: CORM-3 treatment at the time of reperfusion reduces ischemia-reperfusion-induced brain injury by suppressing neuroinflammation and alleviating blood-brain barrier disruption. Our data suggest that CORM-3 may provide an effective therapy for ischemic stroke.

Keywords: Blood-brain barrier; Carbon monoxide; Carbon monoxide-releasing molecule-3; Cerebral ischemia; Neuroinflammation.

MeSH terms

  • Acetyltransferases / metabolism
  • Animals
  • Anti-Inflammatory Agents / therapeutic use*
  • Blood-Brain Barrier / drug effects*
  • Blood-Brain Barrier / physiopathology
  • Brain Edema / drug therapy
  • Brain Edema / etiology
  • Calcium-Binding Proteins / metabolism
  • Cerebral Infarction / drug therapy
  • Cerebral Infarction / etiology
  • Cytokines / metabolism
  • Disease Models, Animal
  • Encephalitis / etiology*
  • Encephalitis / prevention & control*
  • Gene Expression Regulation / drug effects
  • Infarction, Middle Cerebral Artery* / complications
  • Infarction, Middle Cerebral Artery* / drug therapy
  • Infarction, Middle Cerebral Artery* / pathology
  • Laminin / metabolism
  • Male
  • Mice
  • Mice, Inbred C57BL
  • Microfilament Proteins / metabolism
  • Microglia / drug effects
  • Organometallic Compounds / therapeutic use*
  • Phosphopyruvate Hydratase / metabolism
  • Receptor, Platelet-Derived Growth Factor beta / metabolism
  • Zonula Occludens-1 Protein / metabolism

Substances

  • Aif1 protein, mouse
  • Anti-Inflammatory Agents
  • Calcium-Binding Proteins
  • Cytokines
  • Laminin
  • Microfilament Proteins
  • Organometallic Compounds
  • Tjp1 protein, mouse
  • Zonula Occludens-1 Protein
  • tricarbonylchloro(glycinato)ruthenium(II)
  • Acetyltransferases
  • microtubule-associated protein acetyltransferase
  • Receptor, Platelet-Derived Growth Factor beta
  • Phosphopyruvate Hydratase